Human Recombinant Albumin Segment, by Source to Account Largest Share in Recombinant Albumin Market during 2025-2031

According to our new research study on "Recombinant Albumin Market Forecast to 2031 - Global Analysis - by Source, Application and End User," the market was valued at US$ 3,92,504.79 million in 2024 to US$ 7,67,544.05 million by 2031; the market is expected to register a CAGR of 10.1% during 2025-2031. The Recombinant Albumin Market growth is attributed to the increasing prevalence of liver diseases and associated conditions, advancements in biotechnological manufacturing and product development, and growing demand for albumin in critical care and emergency settings.

The continuous evolution of biotechnological processes includes innovations in products that are safe, have high efficacy, and are readily available. Notably, the development of recombinant human albumin (rHA) using genetically engineered yeast and mammalian cell lines has mitigated risks associated with plasma-derived products, such as pathogen transmission and supply constraints. In 2024, major pharmaceutical companies such as CSL Behring and BioPharma announced the launch of next-generation recombinant albumin products featuring improved purity and longer shelf life, as reported by the International Society for Biological and Environmental Repositories (ISBER). Furthermore, advances in fermentation technology and downstream processing have reduced manufacturing costs, enabling wider distribution and accessibility, especially in emerging markets. The approval of novel formulations with extended shelf stability and optimized pharmacokinetics in countries such as Japan and South Korea in 2023 underscores the technological progress driving market expansion. Additionally, ongoing research into recombinant albumin's application in drug delivery systems and nanomedicine signifies potential future growth avenues.